The objective is to establish the impact of current disease modifying therapies (DMTs) and associated support services on Patient Reported Experience Measures and Patient Reported Outcomes in relation to the treatment and management of Relapsing Multiple Sclerosis in the United Kingdom (UK).
Study Type
OBSERVATIONAL
Enrollment
545
The subjects will receive Rebif as per the current practices or as directed by the physician.
The subjects will receive other DMTs as per the current practices or as directed by the physician.
Please contact the
Merck KGaA Communication Center For Locations, United Kingdom
Treatment Satisfaction
The survey sample size has been calculated based on the TSQM-9 questionnaire in order to compare scores between both patient cohorts.
Time frame: 96 weeks
Work Productivity
Work Productivity and Activity Impairment (WPAI) Questionnaire
Time frame: 96 weeks
Health Related Quality of Life
Multiple Sclerosis Impact Scale (MSIS-29) v2.0 Questionnaire
Time frame: 96 weeks
Health Related Quality of Life EuroQoL (EQ-5D)-5L Questionnaire
Time frame: 96 weeks
Device satisfaction
Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ) is an MS-specific treatment satisfaction questionnaire that evaluates injection system satisfaction and side effects.
Time frame: 96 weeks
Evaluation of support services
Patient evaluation of Manufacturer, Homecare and NHS support services
Time frame: 96 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.